Latest Close
$1.97
Stock Hub
ACXP
Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. Use the sections below to move between chart, technical analysis, fundamentals, and news.
1y Change
-$6.03 (-75.37%)
Market Cap
$8,466,544.00
Sector
Healthcare
Industry
Biotechnology
Recommendation
strong_buy
52W Range
$1.33 to $21.00
Target Mean Price
$17.00
Beta
Not available
Trailing P/E
Not available
Forward P/E
-0.92
Price / Book
0.95
Company Overview
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.